Patents Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE
-
Patent number: 11473145Abstract: The inventors initially participated to the identification of LPIN1 mutations as a cause for massive rhabdomyolysis episodes in children, triggered by febrile illness. The inventors have suggested that TLR9 antagonists would be suitable for the treatment of rhabdomyolysis (WO2017085115). The inventors thus treated 2 patients with lipin-1 disease by a TRL9 antagonist (hydroxychloroquine). They showed that the accumulation of mtDNA in plasma of the two patients before treatment decreases under treatment. When the treatment was stopped, the accumulation of mtDNA reappeared, then normalized when treatment was resumed. Accordingly, the present invention relates to a method for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist comprising determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient (e.g. by PCR).Type: GrantFiled: July 26, 2018Date of Patent: October 18, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), FOUNDATION IMAGING, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE PARISInventors: Pascale De Lonlay-Debeney, Peter Van Endert, Marine Madrange, Yamina Hamel, François-Xavier Mauvais
-
Patent number: 11472844Abstract: The invention relates to a peptidomimetic comprising or consisting of a D amino-acid sequence having at least 75% identity with SEQ ID NO: 1 or SEQ ID NO: 2, or variants or fragments thereof, in particular a peptidomimetic having the capability to interact at least with: neutrophils and/or neutrophil granules, and/or lactoferrin, and/or globet-cells and/or Muc2 proteins, and/or mucus and/or airway sputum. The peptidomimetic may have the capacity to adopt a multimeric, especially a trimeric, organization, and can be labelled, or associated with a reporter or a carrier entity, or associated with an active molecule. The invention also relates to a Solid-Phase Synthesis method for synthesizing a peptidomimetic of the invention, compositions comprising the same and use of the peptidomimetics as a medicamentor an inflammation marker or a neutrophilic inflammation marker.Type: GrantFiled: December 11, 2018Date of Patent: October 18, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEURInventors: Benoit Sebastien Marteyn, Yves-Marie Coic, Francoise Baleux
-
Patent number: 11460467Abstract: The present invention relates to an in vitro method for diagnosing lupus in a subject, said method comprising the step of detecting in a biological sample obtained from the subject the autoantibody recognizing the protein biomarker THEX1. More, the invention relates to kits and array useful for carrying out diagnosis methods according to the present invention.Type: GrantFiled: February 7, 2019Date of Patent: October 4, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université d'Aix Marseille, GFRS (Groupe Francophone de Recherche sur la Sclerodermie Systemique)Inventors: Nathalie Lambert, Fanny Arnoux, Doua Azzouz
-
Patent number: 11458118Abstract: Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.Type: GrantFiled: April 20, 2018Date of Patent: October 4, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE BRETAGNE OCCIDENTALE, ETABLISSEMENT FRANÇAIS DU SANG (EFS), CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BRESTInventors: Pascal Trouve, Claude Ferec, Mathieu Kerbiriou, Florentin Huguet
-
Patent number: 11458194Abstract: The inventors have developed a metastatic 4T1 breast tumor model in BALB/c mice. They have shown that the vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher anti-tumoral response against breast cancer and inhibits metastasis development. They established that these responses are achieved only by the addition of valproic acid in the therapeutic regimen in comparison to the use ESCs or iPSCs alone. Thus, the inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to i) a population of pluripotent cells and ii) a compound selected from a group which activates MHC expression, as a combined preparation for use in a method for treating a subject suffering from a cancer, comprising a step of administering simultaneously, separately or sequentially to said subject a therapeutically amount thereof.Type: GrantFiled: May 24, 2017Date of Patent: October 4, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITE PARIS-SACLAY, UNIVERSITE PARIS CITEInventors: Frank Griscelli, Ali Turhan, Annelise Bennaceur Griscelli
-
Patent number: 11440906Abstract: The present disclosure relates to biguanide derivatives of formula (I) and their rearrangement products. The present disclosure also relates to the use of these compounds in a method for treating cancer, in particular melanoma.Type: GrantFiled: December 21, 2018Date of Patent: September 13, 2022Assignees: Centre National de la Recherche Scientifique, INSERM (Institut National de la Santé et de la Recherche Médicale), Université Côte d'AzurInventors: Rachid Benhida, Stephane Rocchi, Cyril Ronco, Emile Jaune, Oleksandr Grytsai, Nedra Tekaya
-
Publication number: 20220273582Abstract: A continuous process for nano-emulsification that is performed by concentration phase inversion in a microfluidic reactor, including the following steps: (a) injection of an aqueous phase into a first microchannel, the first microchannel opening onto a formulation chamber, (b) injection, into a second microchannel, of a fatty phase including one or more fatty substances immiscible in the aqueous phase, and one or more surfactants, the second microchannel opening into the formulation chamber, then (c) mixing of the aqueous phase and the fatty phase in the formulation chamber, then (d) recovering, at the output of the formulation chamber, a suspension including lipid nanocapsules. Also, the lipid nanocapsules obtainable by the process, and the use of the lipid nanocapsules as nanovectors for pharmacologically active ingredients.Type: ApplicationFiled: July 24, 2020Publication date: September 1, 2022Applicants: UNIVERSITÉ D'ANGERS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Brice CALVIGNAC, Jean-Christophe GIMEL, Emilie ROGER, Nicolas ROLLEY, Guillaume LEFEBVRE, Guillaume BASTIAT, Florian FOUCHET, Kévin MATHA
-
Publication number: 20220275105Abstract: A method for providing cardioprotection in a subject who experienced a myocardial infarction, including administering a therapeutically effective amount of a Granzyme B inhibitor. Following acute MI in mice, CD8+ T lymphocytes are quickly recruited and activated in ischemic heart tissue, and release Granzyme B, leading to cardiomyocyte apoptosis and deterioration of myocardial function. Antibody-mediated depletion of CD8+ T lymphocytes decreases Granzyme B content and apoptotic within the myocardium and inflammatory response. mAb mediated-CD8 depletion limits myocardial injury and improves heart function. These effects are recapitulated in mice with CD8+ T cell selective Granzyme B deficiency in mice. Granzyme B is produced by other cell types (e.g., NK cells). Global Granzyme B deletion (GzmB-/- mice) decreases apoptotic within the myocardium, reduces local pro-inflammatory signature and ultimately limits infarct size after MI.Type: ApplicationFiled: July 31, 2020Publication date: September 1, 2022Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), SORBONNE UNIVERSITÉ, UNIVERSITÉ DE PARISInventors: Hafid AIT-OUFELLA, Nicolas DANCHIN, Icia SANTOS ZAS, Tabassome SIMON
-
Patent number: 11427836Abstract: An RNA interference (RNAi) strategy is provided based on use of artificial microRNA (amiR) to reduce NKCC1 expression. In particular, a method is provided that achieves neuron-specific expression of specific amiR against NKCC1 by using a human Synapsin promoter to drive transgene expression.Type: GrantFiled: April 11, 2018Date of Patent: August 30, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITE D'EVRY-VAL-D'ESSONNE, GENETHON, FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, FONDAZIONE TELETHONInventors: Federico Mingozzi, Giuseppe Ronzitti, Andrea Contestabile, Laura Cancedda
-
Patent number: 11427824Abstract: The present invention relates to compositions and methods for the treatment of myotonic dystrophy.Type: GrantFiled: October 27, 2017Date of Patent: August 30, 2022Assignees: GENETHON, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Ana Maria Buj Bello, Mirella Lo Scrudato
-
Patent number: 11427648Abstract: The present invention relates to the field of diagnostic and treatment of cancer, particularly melanoma, pancreatic cancer, kidney cancer and colon cancer. In particular, the invention relates to an antibody directed specifically to CD146-positive tumors and its applications, particularly for use as a medicament for the prevention and/or treatment of cancer, for use in a method of diagnostic or prognostic of a cancer, or for use as a radiotracer when labelled with a radioactive element.Type: GrantFiled: October 5, 2018Date of Patent: August 30, 2022Assignees: UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Marcel Blot-Chabaud, Benjamin Guillet, Marie Nollet, Jimmy Stalin, Nathalie Bardin, Françoise Dignat-George
-
Publication number: 20220251232Abstract: Novel anti-CD25 antibodies and antigen-bind fragments thereof that do not inhibit the binding of interleukin-2 (IL-2) to CD25, and the use thereof for treating cancer or an infectious disease. Also, fusion proteins including the antibodies and antigen-bind fragments, nucleic acids encoding the antibodies and antigen-bind fragments, and an expression vectors including the nucleic acids. Further, pharmaceutical compositions including the fusion proteins or the antibodies and antigen-bind fragments.Type: ApplicationFiled: May 20, 2020Publication date: August 11, 2022Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX MARSEILLE, UNIVERSITE DE PARIS, ALDERAAN BIOTECHNOLOGY, UNIVERSITE PARIS EST CRETEIL VAL DE MARNEInventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Arnaud FOUSSAT
-
Patent number: 11406686Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of tissue lesions. The inventors showed that CCR2 is expressed on FMCs, especially on a subpopulation of progenitor cells, that they call “fetal myeloid progenitor cells” (FMPCs), and mediates the recruitment of these cells to maternal wound tissue. Moreover, the inventors reported that recruited FMCs/FMPCs improve maternal skin wound healing by organizing blood vessel endothelium and secreting pro-angiogenesis peptides, particularly chemokine CXCL1, to enhance angiogenesis in wound. In particular, the present invention relates to CCR2 agonists for use in the treatment of tissue lesions in a subject in need thereof.Type: GrantFiled: May 2, 2017Date of Patent: August 9, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Sorbonne Université, Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (APHP)Inventors: Selim Aractingi, Mathieu Catela, Dany Nassar, Zhe Wang
-
Publication number: 20220233673Abstract: A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.Type: ApplicationFiled: June 4, 2020Publication date: July 28, 2022Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), COMMISSARIAT Á L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Anne BILLET, Frédéric SCHMIDT, Ludger JOHANNES, Denis SERVENT, Gilles MOURIER, Éric TARTOUR, Michael KAY, James M. FULCHER
-
Publication number: 20220233250Abstract: Systems, instruments, and methods are provided verifying the surgery is being performed in accordance with a surgical plan, wherein a surgical tool having a sensor outputs a data signal that enables the trajectory of the surgical tool to be displayed as an overlay on an image of an anatomical portion of a patient and a visual or audible signal that confirms the surgical tool is penetrating the anatomical portion in accordance with the surgical plan and/or that issues an alert indicating that the surgical tool is not being inserted into the anatomical portion according to the surgical plan.Type: ApplicationFiled: April 13, 2022Publication date: July 28, 2022Applicants: SpineGuard, INSERM (Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique - CNRSInventors: Stephane BETTE, Maurice BOURLION, Thibault CHANDANSON
-
Patent number: 11389489Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.Type: GrantFiled: June 8, 2020Date of Patent: July 19, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, UNIVERSITE DE ROUEN, TARGEDYSInventors: Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Naouel Tennoune, Romain Legrand
-
Patent number: 11390866Abstract: The present invention relates to a nucleic acid sequence derived from the regulatory region of the human gamma-synuclein gene and having a promoter activity in retinal ganglion cells. The present invention also relates to expression cassettes or vectors comprising said promoter operably linked to a nucleic acid sequence encoding a polypeptide of interest as well as viral particles or host cells comprising said expression cassette or vector. The present invention also relates to the use of said expression cassettes, vectors, viral particles or cells in the treatment of ocular disease, in particular ocular disease associated with retinal ganglion cell or photoreceptor cell degeneration.Type: GrantFiled: December 5, 2016Date of Patent: July 19, 2022Assignees: SORBONNE UNIVERSITÉ, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Deniz Dalkara, Serge Picaud, Melissa Desrosiers, Jose-Alain Sahel, Jens Duebel, Alexis Bemelmans, Botond Roska
-
Patent number: 11385231Abstract: The present invention relates to methods for predicting the survival time of patients suffering from a lung cancer.Type: GrantFiled: August 26, 2016Date of Patent: July 12, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE SCIENTIFIQUE), UNIVERSITE DE PARIS, SORBONNE UNIVERSITE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)Inventors: Marie-Caroline Dieu-Nosjean, Wolf Herdman Fridman, Catherine Sautes-Fridman, Priyanka Devi
-
Patent number: 11382894Abstract: The inventors demonstrate that the phosphatase and hydrolase domains of soluble epoxide hydrolase (sEH) regulate the cardiovascular calcification process and revealed that inhibition of the phosphatase domain of sEH could represent a new pharmacological target in the prevention of cardiovascular calcification. The present invention thus relates to a therapeutically effective amount of an inhibitor of phosphatase activity of soluble epoxide hydrolase for use in a method of treating cardiovascular calcification in a subject in need thereof.Type: GrantFiled: March 29, 2018Date of Patent: July 12, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE ROUEN NORMANDIE, UNIVERSITE DE PICARDIE JULES VERNE, CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, CENTRE HOSPITALIER UNIVERSITAIRE D'AMIENSInventors: Jeremy Bellien, Isabelle Six, Romuald Mentaverri, Said Kamel
-
Patent number: 11384351Abstract: The present invention relates to the field of nucleic acid purification. In particular, it relates to methods and tools for purifying nucleic acids in a sample; which are compatible with high-throughput sequencing and diagnosis. The inventors have shown that nucleic acid binding proteins recruited to polymerized tubulin (i.e. microtubules) could, subsequently, be isolated from cell lysates. Surprisingly, it has now been found that the amount of recovered nucleic acid found in these microtubule pellets increases dramatically in the presence of nucleic acid-trapping proteins comprising a nucleic acid-binding moiety and a polymerized tubulin-binding moiety, by comparison to proteins devoid of the nucleic acid-binding moiety; and that the recovery of the purified nucleic acids was itself particularly efficient. This purification method is particularly amenable to high-throughput sequencing and/or in the context of a diagnosis method for identifying or comparing the amount of nucleic acids in a set of samples.Type: GrantFiled: July 27, 2018Date of Patent: July 12, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'EVRY—VAL D'ESSONEInventors: David Pastre, Bénédicte Desforges, Alexandre Maucuer